Insmed Current Ratio 2006-2021 | INSM

Insmed current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Insmed Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.04B $0.10B 10.42
2021-03-31 $0.50B $0.08B 6.16
2020-12-31 $0.62B $0.12B 5.24
2020-09-30 $0.67B $0.08B 7.95
2020-06-30 $0.71B $0.08B 8.98
2020-03-31 $0.49B $0.07B 6.89
2019-12-31 $0.56B $0.09B 6.51
2019-09-30 $0.60B $0.09B 6.98
2019-06-30 $0.65B $0.09B 7.54
2019-03-31 $0.46B $0.09B 4.82
2018-12-31 $0.52B $0.08B 6.51
2018-09-30 $0.58B $0.06B 10.06
2018-06-30 $0.65B $0.05B 14.14
2018-03-31 $0.70B $0.04B 20.01
2017-12-31 $0.39B $0.05B 8.72
2017-09-30 $0.44B $0.03B 15.21
2017-06-30 $0.10B $0.03B 3.67
2017-03-31 $0.13B $0.02B 5.66
2016-12-31 $0.17B $0.03B 6.02
2016-09-30 $0.21B $0.02B 8.79
2016-06-30 $0.23B $0.03B 7.10
2016-03-31 $0.26B $0.03B 10.12
2015-12-31 $0.29B $0.02B 12.94
2015-09-30 $0.32B $0.05B 6.84
2015-06-30 $0.34B $0.04B 7.94
2015-03-31 $0.14B $0.04B 3.41
2014-12-31 $0.17B $0.02B 8.39
2014-09-30 $0.17B $0.02B 8.03
2014-06-30 $0.09B $0.02B 3.97
2014-03-31 $0.11B $0.02B 5.31
2013-12-31 $0.12B $0.02B 7.06
2013-09-30 $0.13B $0.02B 6.55
2013-06-30 $0.08B $0.02B 4.34
2013-03-31 $0.08B $0.02B 4.10
2012-12-31 $0.09B $0.02B 5.94
2012-09-30 $0.09B $0.01B 13.81
2012-06-30 $0.07B $0.01B 11.39
2012-03-31 $0.07B $0.00B 17.16
2011-12-31 $0.08B $0.00B 17.29
2011-09-30 $0.08B $0.00B 22.81
2011-06-30 $0.09B $0.00B 26.52
2011-03-31 $0.10B $0.00B 23.09
2010-12-31 $0.11B $0.00B 32.58
2010-09-30 $0.13B $0.00B 54.49
2010-06-30 $0.13B $0.00B 41.52
2010-03-31 $0.13B $0.00B 50.67
2009-12-31 $0.13B $0.00B 44.81
2009-09-30 $0.12B $0.00B 34.19
2009-06-30 $0.12B $0.01B 26.69
2009-03-31 $0.13B $0.01B 9.54
2008-12-31 $0.00B $0.01B 0.53
2008-09-30 $0.01B $0.00B 1.36
2008-06-30 $0.01B $0.01B 1.70
2008-03-31 $0.01B $0.00B 3.22
2007-12-31 $0.02B $0.00B 4.61
2007-09-30 $0.02B $0.00B 5.14
2007-06-30 $0.02B $0.00B 7.29
2007-03-31 $0.01B $0.01B 1.81
2006-12-31 $0.03B $0.01B 2.63
2006-09-30 $0.04B $0.01B 6.02
2006-06-30 $0.05B $0.01B 8.35
2006-03-31 $0.06B $0.00B 17.48
2005-12-31 $0.02B $0.01B 3.94
2005-09-30 $0.02B $0.00B 5.25
2005-06-30 $0.03B $0.00B 7.35
2005-03-31 $0.04B $0.00B 8.72
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.164B $0.164B
Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76